<DOC>
	<DOCNO>NCT01262911</DOCNO>
	<brief_summary>SRT2379 potent small molecule activator SIRT1 find inhibit systemic inflammation induce intravenous injection lipopolysaccharide ( LPS ) mouse . The objective study test SRT2379 may novel compound treatment inflammatory disorder man .</brief_summary>
	<brief_title>Effect SRT2379 Endotoxin-Induced Inflammation</brief_title>
	<detailed_description />
	<criteria>Healthy , determine responsible experienced physician , base medical evaluation include medical history , physical examination laboratory test carry within 21 day prior dose . Male 18 35 year age inclusive , time signing informed consent Capable give write informed consent , include compliance requirement restriction list consent form Chemistry panel , include renal liver function test , without clinically relevant abnormality Subjects must agree partner use doublebarrier birth control abstinence participate study 7 day follow dose study drug Subject major illness past 3 month significant chronic medical illness investigator would deem unfavorable enrollment include inflammatory disease Subjects history type malignancy exception successfully treat basal cell cancer skin Subject past current gastrointestinal disease may influence drug absorption The subject know positive test hepatitis C antibody , hepatitis B surface antigen HIV Current chronic history liver disease , know hepatic biliary abnormality ( exception Gilbert 's syndrome asymptomatic gallstone ) Subject history , within three year , drug abuse ( include benzodiazepine , opioids , amphetamine , cocaine , THC ) positive drug result Screening visit History alcoholism and/or drink 3 drink per day . Alcoholism define average weekly intake &gt; 21 unit male &gt; 14 unit female . One unit equivalent 8 g alcohol : halfpint ( ~240 mL ) beer , 1 glass ( 125 mL ) wine 1 ( 25 mL ) measure spirit The subject participate clinical trial receive investigational product within three month dose current study Use prescription nonprescription drug , herbal dietary supplement within 7 day unless opinion Investigator Medical Monitor medication interfere study procedure compromise subject safety Subject difficultly donate blood accessibility vein leave right arm Subject donate 350 mL blood last 3 month Subject us tobacco product Any clinically relevant abnormality note 12lead ECG judge investigator average QTcB QTcF &gt; 450 msec Any issue , opinion Principal Investigator , would could harmful subject compromise interpretation data Prior participation trial subject receive IV LPS</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>